NeuBase Therapeutics (NASDAQ:NBSE) saw a large decrease in short interest in October. As of October 15th, there was short interest totalling 87,300 shares, a decrease of 34.7% from the September 15th total of 133,700 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 83,600 shares, the days-to-cover ratio is presently 1.0 days.
NBSE has been the subject of several analyst reports. ValuEngine lowered shares of NeuBase Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 16th. BTIG Research initiated coverage on shares of NeuBase Therapeutics in a report on Tuesday, September 24th. They issued a “buy” rating and a $15.00 target price for the company.
NeuBase Therapeutics stock traded up $0.05 during midday trading on Monday, hitting $4.57. The stock had a trading volume of 29,400 shares, compared to its average volume of 152,291. NeuBase Therapeutics has a 52-week low of $1.60 and a 52-week high of $6.95.
NeuBase Therapeutics (NASDAQ:NBSE) last released its earnings results on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter.
About NeuBase Therapeutics
NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.
Read More: What is the quiet period?
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
